Hyperfine (HYPR) Other financing activities (2021)

Hyperfine (HYPR) reported Other financing activities of -$3.5 million for Q4 2021, down 224.61% quarter-over-quarter from $2.8 million in Q2 2021.

Hyperfine (HYPR) Other financing activities (2021) Analysis & Trends

Hyperfine has reported Other financing activities for 1 years, with the latest figure at -$3.5 million in Q4 2021.

For the quarter ending Q4 2021, Other financing activities changed N/A year-over-year to -$3.5 million; the trailing twelve-month figure through Dec 2021 stood at $7000.0 (changed N/A YoY), and the FY2021 full-year result was $7000.0, down 99.3% from the prior year.
Other financing activities for Q4 2021 stood at -$3.5 million, down from $2.8 million in the prior quarter.
The five-year high for Other financing activities was $2.8 million in Q2 2021, with the low at -$3.5 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Hyperfine	155.82 Mn	114.55 Mn	1.98 Mn

Download Data